Greenwich Stock Analysis

GLSI -  USA Stock  

USD 8.50  0.55  6.92%

The big decline in price over the last few months for Greenwich Lifesciencesmay raise some interest from stockholders. The stock closed today at a share price of 8.50 on 217,300 in trading volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Greenwich Lifesciences or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.67. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Greenwich Lifesciences partners.
Please check Risk vs Return Analysis.
  
Refresh
The Greenwich Lifesciences stock analysis report makes it easy to digest most publicly released information about Greenwich Lifesciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Greenwich Stock analysis module also helps to analyze the Greenwich Lifesciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Greenwich Stock Analysis Notes

About 77.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.46. Greenwich Lifesciences had not issued any dividends in recent years. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To learn more about Greenwich Lifesciences call the company at 832 819 3232 or check out https://greenwichlifesciences.com.

Greenwich Lifesciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Greenwich Lifesciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Greenwich Lifesciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Greenwich Lifesciences generated a negative expected return over the last 90 days
Greenwich Lifesciences has high historical volatility and very poor performance
Net Loss for the year was (5.94 M).
Greenwich Lifesciences currently holds about 19.74 M in cash with (5.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 77.0% of the company shares are held by company insiders

Greenwich Lifesciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Greenwich Lifesciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Greenwich Lifesciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Greenwich Lifesciences specific information freely available to individual and institutional investors to make a timely investment decision.
16th of May 2022
Other Events
View
15th of December 2021
Submission of Matters to a Vote of Security Holders
View
13th of December 2021
Financial Statements and Exhibits. Other Events
View
10th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View

Greenwich Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Greenwich Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Greenwich Lifesciences backward and forwards among themselves. Greenwich Lifesciences' institutional investor refers to the entity that pools money to purchase Greenwich Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares375.2 K7.4 M
Blackrock IncCommon Shares236.3 K4.6 M
Geode Capital Management LlcCommon Shares69.7 K1.4 M
State Street CorpCommon Shares66.5 K1.3 M
Ameriprise Financial IncCommon Shares42.7 K837 K
Northern Trust CorpCommon Shares35.1 K688 K
Morgan StanleyCommon Shares21.7 K426 K
Note, although Greenwich Lifesciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Greenwich Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 103.87 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Greenwich Lifesciences's market, we take the total number of its shares issued and multiply it by Greenwich Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Greenwich Profitablity

Greenwich Lifesciences' profitability indicators refer to fundamental financial ratios that showcase Greenwich Lifesciences' ability to generate income relative to its revenue or operating costs. If, let's say, Greenwich Lifesciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Greenwich Lifesciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Greenwich Lifesciences' profitability requires more research than a typical breakdown of Greenwich Lifesciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.16) (0.17) 
Return on Average Equity(0.16) (0.16) 
Return on Invested Capital 8.44  7.81 

Management Efficiency

The entity has return on total asset (ROA) of (14.91) % which means that it has lost $14.91 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (24.13) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences management efficiency ratios could be used to measure how well greenwich lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.17. The current Return on Invested Capital is estimated to decrease to 7.81. Greenwich Lifesciences Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 17,852.4. The current Goodwill and Intangible Assets is estimated to increase to about 14.2 K, while Total Assets are projected to decrease to roughly 22.4 M.
Last ReportedProjected for 2022
Book Value per Share 2.07  2.24 
Enterprise Value over EBIT(64.00) (69.05) 
Enterprise Value over EBITDA(63.58) (68.60) 
Price to Book Value 11.90  12.11 
Tangible Assets Book Value per Share 2.10  1.91 
Enterprise Value290.4 M305.1 M
Tangible Asset Value27.2 M22.4 M

Technical Drivers

As of the 28th of May, Greenwich Lifesciences retains the risk adjusted performance of (0.32), and Market Risk Adjusted Performance of (22.71). Greenwich Lifesciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Greenwich Lifesciences, which can be compared to its competitors. Please check out Greenwich Lifesciences variance, as well as the relationship between the value at risk and skewness to decide if Greenwich Lifesciences is priced fairly, providing market reflects its last-minute price of 8.5 per share. Given that Greenwich Lifesciences has jensen alpha of (1.10), we strongly advise you to confirm Greenwich Lifesciences's regular market performance to make sure the company can sustain itself at a future point.

Greenwich Lifesciences Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
.

Greenwich Lifesciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Greenwich Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Greenwich Lifesciences Predictive Daily Indicators

Greenwich Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Greenwich Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Greenwich Lifesciences Forecast Models

Greenwich Lifesciences time-series forecasting models is one of many Greenwich Lifesciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Greenwich Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Greenwich Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Greenwich Lifesciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Greenwich shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Greenwich Lifesciences. By using and applying Greenwich Stock analysis, traders can create a robust methodology for identifying Greenwich entry and exit points for their positions.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Current Greenwich Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Greenwich analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Greenwich analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
78.0Strong Buy1Odds
Greenwich Lifesciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Greenwich analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Greenwich stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Greenwich Lifesciences, talking to its executives and customers, or listening to Greenwich conference calls.
Greenwich Analyst Advice Details

Greenwich Stock Analysis Indicators

Greenwich Lifesciences stock analysis indicators help investors evaluate how Greenwich Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Greenwich Lifesciences shares will generate the highest return on investment. By understating and applying Greenwich Lifesciences stock analysis, traders can identify Greenwich Lifesciences position entry and exit signals to maximize returns.
Quick Ratio81.86
Fifty Two Week Low7.88
Shares Short Prior Month273.89k
Average Daily Volume Last 10 Day155.32k
Average Daily Volume In Three Month74.02k
Shares Percent Shares Out2.38%
Short Percent Of Float8.28%
Forward Price Earnings-11.10
Float Shares2.94M
Fifty Two Week High48.96
Enterprise Value To Ebitda-13.98
Fifty Day Average15.06
Two Hundred Day Average26.89
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.